Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)‘s stock had its “overweight” rating restated by Piper Jaffray Companies in a report released on Monday. They currently have a $170.00 target price on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target would indicate a potential upside of 22.28% from the company’s previous close.

A number of other equities research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Leerink Swann restated a “buy” rating and issued a $182.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Royal Bank Of Canada began coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price objective for the company. Deutsche Bank AG restated a “buy” rating and issued a $158.00 price objective (up from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $180.00 price objective (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. Alexion Pharmaceuticals has an average rating of “Buy” and an average price target of $154.31.

Shares of Alexion Pharmaceuticals (ALXN) traded down 1.60% during trading on Monday, reaching $136.79. 419,892 shares of the company’s stock traded hands. The company’s 50-day moving average is $142.33 and its 200 day moving average is $127.81. The company has a market cap of $30.53 billion, a price-to-earnings ratio of 59.32 and a beta of 1.39. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. The firm had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business’s quarterly revenue was up 21.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.13 EPS. Equities analysts forecast that Alexion Pharmaceuticals will post $5.60 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/23/piper-jaffray-companies-reiterates-overweight-rating-for-alexion-pharmaceuticals-inc-alxn.html.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the transaction, the director now owns 6,315 shares in the company, valued at $869,828.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the transaction, the director now owns 5,480 shares in the company, valued at approximately $799,038.80. The disclosure for this sale can be found here. Insiders sold 17,190 shares of company stock worth $2,433,669 in the last quarter. 4.35% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio grew its stake in Alexion Pharmaceuticals by 4.6% in the third quarter. Strs Ohio now owns 557,938 shares of the biopharmaceutical company’s stock valued at $78,273,000 after purchasing an additional 24,756 shares during the last quarter. APG Asset Management N.V. grew its stake in Alexion Pharmaceuticals by 15.4% in the third quarter. APG Asset Management N.V. now owns 64,532 shares of the biopharmaceutical company’s stock valued at $9,053,000 after purchasing an additional 8,600 shares during the last quarter. Meeder Asset Management Inc. grew its stake in Alexion Pharmaceuticals by 603.1% in the third quarter. Meeder Asset Management Inc. now owns 3,403 shares of the biopharmaceutical company’s stock valued at $478,000 after purchasing an additional 2,919 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its stake in Alexion Pharmaceuticals by 7.7% in the third quarter. Robeco Institutional Asset Management B.V. now owns 10,605 shares of the biopharmaceutical company’s stock valued at $1,489,000 after purchasing an additional 755 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Alexion Pharmaceuticals by 4,509.0% in the third quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after purchasing an additional 864,967 shares during the last quarter. Institutional investors own 94.25% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.